D-Glucose 6-Phosphate-13C6 (disodium xhydrate)
Based on 1 Customer Validation
D-Glucose 6-Phosphate-13C6 disodium xhydrate is a 13C-labeled D-Glucose 6-phosphate disodium xhydrate. D-Glucose 6-phosphate disodium xhydrate is a key central node metabolite in sugar metabolism, serving as the initial metabolite of glycolysis and pentose phosphate pathway, and also a substrate for glycogen synthesis. D-Glucose 6-phosphate disodium xhydrate can act as a metabolic stress signal, especially when phosphoglucomutase (PGI) is inhibited, activating the mTOR pathway, promoting protein synthesis, and thereby participating in the remodeling process of the heart. D-Glucose 6-phosphate disodium xhydrate can be used in research related to non-insulin-dependent diabetes and heart failure.
For research use only. We do not sell to patients.
- Purity : 99.6%
- Formula: 13C6H11Na2O9P
- Molecular Weight:310.06
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled CAS 56-73-5
-
Appearance Solid
-
Molecular Weight 310.06
-
Formula 13C6H11Na2O9P
-
Color White to off-white
-
SMILES
O[13C@@H]1[13C@H]([13C@@H]([13C@H](O[13CH]1O)[13CH2]OP(O[Na])(O[Na])=O)O)O.[xH2O]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro:
H2O : 250 mg/mL (806.30 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.2252 mL | 16.1259 mL | 32.2518 mL | 80.6296 mL |
| 5 mM | 0.6450 mL | 3.2252 mL | 6.4504 mL | 16.1259 mL | |
| 10 mM | 0.3225 mL | 1.6126 mL | 3.2252 mL | 8.0630 mL | |
| 15 mM | 0.2150 mL | 1.0751 mL | 2.1501 mL | 5.3753 mL | |
| 20 mM | 0.1613 mL | 0.8063 mL | 1.6126 mL | 4.0315 mL | |
| 25 mM | 0.1290 mL | 0.6450 mL | 1.2901 mL | 3.2252 mL | |
| 30 mM | 0.1075 mL | 0.5375 mL | 1.0751 mL | 2.6877 mL | |
| 40 mM | 0.0806 mL | 0.4031 mL | 0.8063 mL | 2.0157 mL | |
| 50 mM | 0.0645 mL | 0.3225 mL | 0.6450 mL | 1.6126 mL | |
| 60 mM | 0.0538 mL | 0.2688 mL | 0.5375 mL | 1.3438 mL | |
| 80 mM | 0.0403 mL | 0.2016 mL | 0.4031 mL | 1.0079 mL | |
| 100 mM | 0.0323 mL | 0.1613 mL | 0.3225 mL | 0.8063 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.